Search alternatives:
non decrease » point decrease (Expand Search), note decreased (Expand Search), fold decrease (Expand Search)
wt decrease » we decrease (Expand Search), _ decrease (Expand Search), awd decreased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a non » _ non (Expand Search)
5 wt » _ wt (Expand Search), 5 ht (Expand Search)
non decrease » point decrease (Expand Search), note decreased (Expand Search), fold decrease (Expand Search)
wt decrease » we decrease (Expand Search), _ decrease (Expand Search), awd decreased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a non » _ non (Expand Search)
5 wt » _ wt (Expand Search), 5 ht (Expand Search)
-
261
-
262
-
263
-
264
-
265
-
266
-
267
Real-time measurements of cAMP in response to IBMX in control and AICAR-treated rat AVMs.
Published 2023Subjects: -
268
-
269
-
270
-
271
All Ca<sub>V</sub>3.3 variants left-shift the voltage dependence of inactivation.
Published 2025Subjects: -
272
-
273
-
274
-
275
-
276
-
277
-
278
Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc
Published 2025“…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
-
279
-
280